Take advantage of globally available knowledge for precision oncology
Genetic information about tumor diseases can pave the way to more effective and tolerable therapies. Make individual decisions based on software-supported molecular pathology diagnoses and take full advantage of precision oncology for your patients.
Individual treatment options are derived from comprehensive genome analyses
The better physicians understand the genetic causes of various cancers, the more precise and individualized the diagnoses and treatment options for patients will become. Targeted and immuno-oncological therapy concepts are becoming increasingly important. Modern molecular methods and comprehensive data evaluation lets us identify biomarkers for these therapies.
How we support your clinical decisions
Diagnostic and molecular pathology laboratories use our software-based in-vitro diagnostic application MH Guide to identify relevant biomarkers in tumor samples, and to provide attending physicians with information on individual therapy options and potentially relevant clinical trials.
This information is summarized in a easy-to-understand patient report. This gives you insight into effective and safe drug treatment options and available clinical trials – entirely in line with precision medicine.
The software compares the patient sample data with current, published biomedical knowledge and drug information. MH Guide provides information about identified, relevant biomarkers and their clinical significance in specific cancer entities.
This brochure is currently being updated and will be available soon.
MH Guide in clinical practice
Various oncologists and clinics work with us and with molecular pathology laboratories, using MH Guide to provide more targeted and individualized treatment decisions.
"With these innovative concepts, we want to better predict both the response to and the tolerability of the therapies we plan for women with ovarian, fallopian tube, and peritoneal cancers."
Prof. Dr. med. Jalid Sehouli,
Cancer Center (CCCC), Berlin
"Diagnosed with ovarian cancer IIIC, MH Guide has changed my life with cancer. "
Jutta Vinzent, long-term ovarian cancer patient, shares her personal story, from diagnosis through standard treatment, to personalized treatment.
MH Guide analysis in seven steps
The oncologist or tumor board establishes the indication for molecular pathology diagnostics.
2. Order molecular diagnostics
The oncologist sends sample material (tumor biopsy or tumor sample) with referral and physician’s letter to their local pathologist, ordering the detection of tumor-relevant mutations.
3. Perform NGS analysis
In addition to examining the tumor, the pathologist (a) performs the NGS analysis or (b) commissions a molecular pathology laboratory to do so.
4. Uploading NGS data to MH Guide
The laboratory performing the NGS analysis uploads the data to the MH Order Portal.
5. Analyze NGS data
MH Guide analyzes the NGS data, compares it with information provided by the Dataome knowledge base, and makes it possible to generate a customized report.
The laboratory processes the MH Guide report, signs it, and sends it to the pathologist in charge. The pathologist creates the findings report with all pathological results and the MH Guide report.
7. Select therapy options
The oncologist receives the findings from the pathologist in charge, including individual therapy options and possible clinical trials.
"Oncologists are often faced with the question: Which drugs will bring the greatest therapeutic success for my patient? This is precisely where we want to provide decision support, based on medical facts. What does the genetic profile of the tumor tell me, and what are the latest medical findings on this case? We bring all this together in MH Guide to help oncologists make sound treatment decisions."
DP Dr. med. Christian Meisel
Chief Medical Officer
In Germany, NGS-based tumor analysis and data evaluation with MH Guide are considered standard care for certain indications (billing via EBM by the pathologist). Insured patients can also request reimbursement from their health insurance company. In addition, analysis can be performed as a private service (for patients with private health insurance or those who pay the costs themselves). Please contact us with any questions: CustomerService@molecularhealth.com
We would be happy to offer you a software demo. Send us your request in writing or call us: +49 6221 43851-150
MH Guide fulfills the highest standards in terms of data privacy and data protection, as well as risk and quality management. Data sovereignty always lies with the user. Confidential patient data is transmitted and stored using advanced encryption standards (SSL/TLS, AES-256).
Our hospital partners
Our software solutions: optimum support for clinical decisions
From sequencing data to patient report – in just minutes
MH Guide quickly and accurately identifies and interprets genetic variants in tumors. The MH Guide report helps treatment providers choose therapy options and clinical trials that match the cancer patient’s molecular profile. MH Guide is an IVD medical device approved in the EU.
Software-assisted analysis of predisposition to hereditary breast and ovarian cancer syndrome (HBOC)
MH Guide/BRCA supports human geneticists in identifying clinically-significant germline variants associated with hereditary breast and ovarian cancer syndrome (HBOC). This involves automated NGS-based analysis of BRCA1/2 and other HBOC-related genes.
The automated analysis of hereditary diseases
Would you like more information?
Please contact us by phone or e-mail:
© 2020 Molecular Health GmbH
© 2021 Molecular Health GmbH
© 2020 Molecular Health GmbH